184 related articles for article (PubMed ID: 7575690)
1. Use of an antibody against the matrix metalloproteinase-generated aggrecan neoepitope FVDIPEN-COOH to assess the effects of stromelysin in a rabbit model of cartilage degradation.
Bayne EK; MacNaul KL; Donatelli SA; Christen A; Griffin PR; Hoerrner LA; Calaycay JR; Ayala JM; Chapman K; Hagmann W
Arthritis Rheum; 1995 Oct; 38(10):1400-9. PubMed ID: 7575690
[TBL] [Abstract][Full Text] [Related]
2. Proteoglycan-degrading activity of human stromelysin-1 and leukocyte elastase in rabbit joints. Quantitation of proteoglycan and a stromelysin-induced HABR fragment of aggrecan in synovial fluid and cartilage.
Olszewski JM; Moore VL; McDonnell J; Williams H; Saphos CA; Green BG; Knight WB; Chapman KT; Hagmann WK; Dorn CP; Hale JJ; Mumford RA
Connect Tissue Res; 1996; 33(4):291-9. PubMed ID: 8834447
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro.
Hughes CE; Caterson B; Fosang AJ; Roughley PJ; Mort JS
Biochem J; 1995 Feb; 305 ( Pt 3)(Pt 3):799-804. PubMed ID: 7531436
[TBL] [Abstract][Full Text] [Related]
4. Quantification of a matrix metalloproteinase-generated aggrecan G1 fragment using monospecific anti-peptide serum.
Lark MW; Williams H; Hoernner LA; Weidner J; Ayala JM; Harper CF; Christen A; Olszewski J; Konteatis Z; Webber R
Biochem J; 1995 Apr; 307 ( Pt 1)(Pt 1):245-52. PubMed ID: 7717983
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase digestion of aggrecan in human cartilage tumours.
Toriyama M; Rosenberg AE; Mankin HJ; Fondren T; Treadwell BV; Towle CA
Eur J Cancer; 1998 Nov; 34(12):1969-73. PubMed ID: 10023324
[TBL] [Abstract][Full Text] [Related]
6. Immunolocalization of the cleavage of the aggrecan core protein at the Asn341-Phe342 bond, as an indicator of the location of the metalloproteinases active in the lysis of the rat growth plate.
Lee ER; Lamplugh L; Leblond CP; Mordier S; Magny MC; Mort JS
Anat Rec; 1998 Sep; 252(1):117-32. PubMed ID: 9737748
[TBL] [Abstract][Full Text] [Related]
7. Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent.
Fosang AJ; Last K; Maciewicz RA
J Clin Invest; 1996 Nov; 98(10):2292-9. PubMed ID: 8941646
[TBL] [Abstract][Full Text] [Related]
8. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints.
Lark MW; Bayne EK; Flanagan J; Harper CF; Hoerrner LA; Hutchinson NI; Singer II; Donatelli SA; Weidner JR; Williams HR; Mumford RA; Lohmander LS
J Clin Invest; 1997 Jul; 100(1):93-106. PubMed ID: 9202061
[TBL] [Abstract][Full Text] [Related]
9. Aggrecan degradation in human intervertebral disc and articular cartilage.
Sztrolovics R; Alini M; Roughley PJ; Mort JS
Biochem J; 1997 Aug; 326 ( Pt 1)(Pt 1):235-41. PubMed ID: 9337874
[TBL] [Abstract][Full Text] [Related]
10. Cartilage metabolism in the injured and uninjured knee of the same patient.
Dahlberg L; Roos H; Saxne T; Heinegård D; Lark MW; Hoerrner LA; Lohmander LS
Ann Rheum Dis; 1994 Dec; 53(12):823-7. PubMed ID: 7864691
[TBL] [Abstract][Full Text] [Related]
11. Detection of aggrecanase- and MMP-generated catabolic neoepitopes in the rat iodoacetate model of cartilage degeneration.
Janusz MJ; Little CB; King LE; Hookfin EB; Brown KK; Heitmeyer SA; Caterson B; Poole AR; Taiwo YO
Osteoarthritis Cartilage; 2004 Sep; 12(9):720-8. PubMed ID: 15325638
[TBL] [Abstract][Full Text] [Related]
12. Development of a cleavage-site-specific monoclonal antibody for detecting metalloproteinase-derived aggrecan fragments: detection of fragments in human synovial fluids.
Fosang AJ; Last K; Gardiner P; Jackson DC; Brown L
Biochem J; 1995 Aug; 310 ( Pt 1)(Pt 1):337-43. PubMed ID: 7544117
[TBL] [Abstract][Full Text] [Related]
13. Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro.
Little CB; Flannery CR; Hughes CE; Mort JS; Roughley PJ; Dent C; Caterson B
Biochem J; 1999 Nov; 344 Pt 1(Pt 1):61-8. PubMed ID: 10548534
[TBL] [Abstract][Full Text] [Related]
14. The 45 kDa collagen-binding fragment of fibronectin induces matrix metalloproteinase-13 synthesis by chondrocytes and aggrecan degradation by aggrecanases.
Stanton H; Ung L; Fosang AJ
Biochem J; 2002 May; 364(Pt 1):181-90. PubMed ID: 11988091
[TBL] [Abstract][Full Text] [Related]
15. Analysis of aggrecan in human knee cartilage and synovial fluid indicates that aggrecanase (ADAMTS) activity is responsible for the catabolic turnover and loss of whole aggrecan whereas other protease activity is required for C-terminal processing in vivo.
Sandy JD; Verscharen C
Biochem J; 2001 Sep; 358(Pt 3):615-26. PubMed ID: 11535123
[TBL] [Abstract][Full Text] [Related]
16. Changes in cartilage proteoglycan aggrecan after intra-articular injection of interleukin-1 in rabbits: studies of synovial fluid and articular cartilage.
Lundberg C; Asberg I; Ionescu M; Reiner A; Smedegård G; Poole AR
Ann Rheum Dis; 1996 Aug; 55(8):525-34. PubMed ID: 8774180
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies recognizing protease-generated neoepitopes from cartilage proteoglycan degradation. Application to studies of human link protein cleavage by stromelysin.
Hughes CE; Caterson B; White RJ; Roughley PJ; Mort JS
J Biol Chem; 1992 Aug; 267(23):16011-4. PubMed ID: 1379586
[TBL] [Abstract][Full Text] [Related]
18. A longitudinal study of cartilage matrix metabolism in patients with cruciate ligament rupture--synovial fluid concentrations of aggrecan fragments, stromelysin-1 and tissue inhibitor of metalloproteinase-1.
Dahlberg L; Fridén T; Roos H; Lark MW; Lohmander LS
Br J Rheumatol; 1994 Dec; 33(12):1107-11. PubMed ID: 8000736
[TBL] [Abstract][Full Text] [Related]
19. VDIPEN, a metalloproteinase-generated neoepitope, is induced and immunolocalized in articular cartilage during inflammatory arthritis.
Singer II; Kawka DW; Bayne EK; Donatelli SA; Weidner JR; Williams HR; Ayala JM; Mumford RA; Lark MW; Glant TT
J Clin Invest; 1995 May; 95(5):2178-86. PubMed ID: 7537757
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinases are involved in C-terminal and interglobular domain processing of cartilage aggrecan in late stage cartilage degradation.
Little CB; Hughes CE; Curtis CL; Janusz MJ; Bohne R; Wang-Weigand S; Taiwo YO; Mitchell PG; Otterness IG; Flannery CR; Caterson B
Matrix Biol; 2002 Apr; 21(3):271-88. PubMed ID: 12009333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
